Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV001822362 | SCV002066645 | uncertain significance | not specified | 2020-10-29 | criteria provided, single submitter | clinical testing | DNA sequence analysis of the ANKRD26 gene demonstrated a sequence change, c.2151G>A, in exon 20 that results in an amino acid change, p.Met717Ile. This sequence change does not appear to have been previously described in patients with ANKRD26-related disorders. This sequence change has been described in the gnomAD database with a low overall population frequency of 0.012% and a frequency of 0.087% in the Latino sub group (dbSNP rs188446159). The p.Met717Ile change affects a poorly conserved amino acid residue of the ANKRD26 protein. The p.Met717Ile substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Met717Ile change remains unknown at this time. |
Labcorp Genetics |
RCV002545163 | SCV003249050 | benign | not provided | 2024-11-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004946749 | SCV005447959 | uncertain significance | Inborn genetic diseases | 2024-11-22 | criteria provided, single submitter | clinical testing | The p.M717I variant (also known as c.2151G>A), located in coding exon 20 of the ANKRD26 gene, results from a G to A substitution at nucleotide position 2151. The methionine at codon 717 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |